Original Paper

Drug susceptibility testing of clinical isolates of *Candida* albicans against Amphotericin B and Ketoconazole by microdilution and disk diffusion methods

Kazemi A (Ph.D)¹, Nowrozi H (Ph.D)*², Badiee Moghadam M (Pharm.D)³

¹Assistant Professor, Department of Nursing, College of Medical Sciences, Varamin- Pishva Branch, Islamic Azad University, Varamin, Iran. ²Assistant Professor, Department of Laboratory Sciences, Faculty of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran. ³Departments of Pharmaceutics, Islamic Azad University, Pharmaceutical Sciences Branch, Tehran, Iran.

Abstract

Background and Objective: *Candida albicans* is the normal flora of the body as opportunistic fungi. It causes candidiasis in immunocompromised condition. This study was done to drug susceptibility testing of *Candida albicans* isolated from patients against Amphotericin B and Ketoconazole.

Methods: In this descriptive – analytic study, drug susceptibility of 30 *Candida albicans* isolated from patients admitted to Tehran hospitals, Iran was tested against Amphotericin B and Ketoconazole by micro dilution method in accordance with CLSI M27-A2 guideline and disk diffusion method in accordance with CLSI M44-S2 guideline. Standard isolate *Candida albicans* PTCC (5027) and *Candida krusei* PTCC (5295) were used for quality control.

Results: The minimum and maximum MIC against Amphotrericin B was $0.0625 \, \mu g.ml^{-1}$ and $4 \, \mu g.ml^{-1}$, respectively. The minimum and maximum MIC against Ketoconazole was $0.5 \, \mu g/ml^{-1}$ and $32 \, \mu g/ml^{-1}$, respectively. The minimum and maximum zone diameter was 6 and 28 mm for both drugs. The results of drug susceptibility testing by two methods did not show significant differences. 25 isolates (83.3%) against ketoconazole and 2 isolates (6.7%) against Amphotericin B were resistant.

Conclusion: Amphotericin B administration seems better choice in candidiasis treatment in comparision with Ketoconazole.

Keywords: Candida albicans, Amphotericin B, Ketoconazole

Received 30 Apr 2016

Revised 18 Dec 2016

Accepted 31 Dec 2016

^{*} Corresponding Author: Nowrozi H (Ph.D), E-mail: nowrozi.h@iums.ac.ir